Rafael Kraehenmann
Clinical Researcher in Psychopharmacology
Papers
Trials
Key Impact
Noted for experimental human studies elucidating how serotonergic psychedelics (LSD, psilocybin) alter perception, cognition and social processing via 5-HT2A/1A mechanisms, linking receptor pharmacology to phenomenology and potential therapeutic effects.
Background & Research
Rafael Kraehenmann is a clinical researcher specialising in human psychopharmacology and the neuropsychological effects of serotonergic psychedelics. His work focuses on mechanistic, experimentally controlled studies that probe how LSD and psilocybin modulate perception, waking imagery, primary-process thinking and social-cognitive processing through serotonin receptor activity. He has investigated receptor-specific contributions using pharmacological challenge designs (including manipulation of 5-HT2A and 5-HT1A signalling), and has characterised both acute phenomenology and predictors of sustained response after psychedelic experiences in naturalistic and semi-clinical settings such as mindfulness retreats.
Kraehenmann's contributions emphasise bridging subjective report, behavioural measures and neurobiological mechanisms to inform both basic science and clinical translation. Key themes in his publications include the dependence of LSD-elicited dreamlike imagery on 5-HT2A activation, the modulation of psilocybin experiences by co-administered serotonergic agents, effects on social exclusion processing and neuroimaging measures, and attempts to characterise and predict acute and longer-term responses to psilocybin in groups with anxiety-related concerns. His research advances understanding of how receptor-level pharmacology shapes psychedelic phenomenology and potential therapeutic mechanisms.